Pharmaceuticals & Drug Pricing

Over the past 24 hours, the pharmaceuticals and drug pricing landscape has seen emerging clinical data on high-cost specialty therapies—such as deuruxolitinib for severe alopecia areata and CAR therapies for HBV and HIV—that signal both expanded therapeutic options and future cost pressures for Medicare and Medicaid payers operating under new Trump administration leadership at HHS and CMS. These developments underscore the need for value-based care organizations and ACOs to proactively assess risk-sharing and outcomes-based contract models to manage financial exposure as these therapies approach commercialization and coverage decisions. For more detail, see AJMC’s coverage of deuruxolitinib for alopecia areata and CAR therapies for HBV, HIV.